VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $975.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $975.10M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2020 was $654.53M, a 123.44% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2019 was $292.93M, a 132.39% increase from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2018 was $126.05M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $975.10M 10-K · filed 2026-02-13 | |
| 2020-12-31 | $654.53M 10-K · filed 2021-02-11 | |
| 2019-12-31 | $292.93M 10-K · filed 2021-02-11 | |
| 2018-12-31 | $126.05M 10-K · filed 2021-02-11 | |
| 2017-12-31 | -$5.49M 10-K · filed 2020-02-13 | |
| 2016-12-31 | -$23.58M 10-K · filed 2019-02-13 | |
| 2015-12-31 | -$195.23M 10-K · filed 2018-02-15 | |
| 2014-12-31 | -$257.21M 10-K · filed 2017-02-23 | |
| 2013-12-31 | -$219.12M 10-K · filed 2016-02-16 | -$341.64M 10-K · filed 2014-02-11 |
| 2012-12-31 | $11.20M 10-K · filed 2015-02-13 | -$4.33M 10-K · filed 2013-03-01 |
| 2011-12-31 | $21.16M 10-K · filed 2014-02-11 | |
| 2010-12-31 | -$256.57M 10-K · filed 2013-03-01 | |
| 2009-12-31 | -$218.34M 10-K · filed 2012-02-22 | |
| 2008-12-31 | -$156.35M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |